Pemphigus clinical trials
The registry lists 76 studies for Pemphigus across more than 10 countries. 18 are recruiting or about to start. 67 of them are mainly about Pemphigus (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-15.
Get an email when these change. Save the Pemphigus studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
University Hospital, Rouen (6) · Assiut University (5) · argenx (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Cairo University (3) · Assistance Publique - Hôpitaux de Paris (2) · Ruijin Hospital (2) · Principia Biopharma, a Sanofi Company (2)
What is being tested here
Drugs under test in Pemphigus studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 7, phase 3 first
- Dec 2026A Clinical Study of B007 in the Treatment of Pemphigus. · Phase 3 · Shanghai Jiaolian Drug Research and Development Co., Ltd
- Sep 2027ONO-4059 Study in Patients With Steroid-resistant Pemphigus · Phase 3 · Ono Pharmaceutical Co., Ltd.
- Dec 2026CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris · Jinbo Chen
- Mar 2027FARD (RaDiCo Cohort) (RaDiCo-FARD) · Institut National de la Santé Et de la Recherche Médicale, France
- May 2027Rituximab With Corticosteroids Versus Corticosteroids Plus Azathioprine for Moderate-to-Severe Pemphigus Vulgaris · Khyber Teaching Hospital
- Jul 2027Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. · IRIS Research and Development, LLC
- Oct 2027A Single-center Study of CM313 in Patients With Pemphigus · Sichuan Provincial People's Hospital
Who these studies take
Of the 9 Pemphigus studies recruiting now, 4 (44%) set no upper age limit and 2 (22%) stop at 75 or younger. 1 (11%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (11%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (11%) | 1 (11%) |
| 18 | 9 (100%) | 9 (100%) |
| 30 | 9 (100%) | 9 (100%) |
| 40 | 9 (100%) | 9 (100%) |
| 50 | 9 (100%) | 9 (100%) |
| 65 | 9 (100%) | 9 (100%) |
| 75 | 8 (89%) | 8 (89%) |
| 85 | 5 (56%) | 5 (56%) |
Across all 76 studies, recruiting or not: 26% stop at 75 or younger and 9% at 65; 14% take children; 0% are for women only and 0% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 76. Browse all 76 → or search them.
- A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)RecruitingNCT04422912Phase 1/21 country
- Compassionate Use or Expanded Access of DupilumabAvailableNCT04776694
- Rituximab With Corticosteroids Versus Corticosteroids Plus Azathioprine for Moderate-to-Severe Pemphigus VulgarisNot yet recruitingNCT07769333Early Phase 1
- CD19 CAR-T Therapy for Refractory Pemphigus VulgarisRecruitingNCT07681388Not applicable1 country
- Comparison of the Efficacy of Clobetasol Propionate 0.05% Mouthwash, Photobiomodulation, and Their Combination in Managing of Oral Lesions in Patient With Pemphigus Vulgaris.RecruitingNCT07641725Not applicable1 country
- A Clinical Study of B007 in the Treatment of Pemphigus.RecruitingNCT06454357Phase 2/31 country
- Autoimmune Blistering Diseases StudyRecruitingNCT027537771 country
- Comparison of a Personalized Maintenance Therapy With the Standard Treatment in PemphigusRecruitingNCT05898308Phase 42 countries
- FARD (RaDiCo Cohort) (RaDiCo-FARD)RecruitingNCT059544161 country
- Low-level Laser Therapy on Oral Pemphigus Vulgaris Patients.Not yet recruitingNCT06971172Not applicable
- A Single-center Study of CM313 in Patients With PemphigusNot yet recruitingNCT06904040Not applicable1 country
- Impact of a Lifestyle Program on Quality of Life in Pemphigus PatientsNot yet recruitingNCT06901427Not applicable
- Trichoscopy as a Monitoring Tool for Activity and Remission in Pemphigus Vulgaris: A Clinical Study Supported by Immunological Evaluation.Not yet recruitingNCT06863454
- A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.Not yet recruitingNCT06663943Phase 1/2
- Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.RecruitingNCT06581562Phase 11 country
- Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research InitiativesRecruitingNCT056352661 country
- Coagulation Activation in Patients With PemphigusNot yet recruitingNCT06285435
- Evaluation of Galectin-3 in Serum and Saliva of Pemphigus PatientsNot yet recruitingNCT05992727
- Periodontal Status and Disease Severity in Pemphigus Vulgaris PatientsCompletedNCT073842211 country
- ONO-4059 Study in Patients With Steroid-resistant PemphigusActive, not recruitingNCT06696716Phase 31 country
- COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersTerminatedNCT05000216Phase 21 country
- Effect of Topical Insulin on Healing Rate of Pemphigus LesionsCompletedNCT07461103Phase 21 country
- Efficacy and Safety of Different Doses of Rituximab Therapy in Pemphigus PatientsCompletedNCT074579441 country
- Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and DermatologistsCompletedNCT074289151 country
- Identification of Vulnerability Factors in the Course of Pemphigus PatientsCompletedNCT02237313Not applicable1 country
- IVIG With Rituximab vs Rituximab as First Line Treatment of PemphigusActive, not recruitingNCT04400994Phase 21 country
- A Single Cycle of Intravenous Immunoglobulin as Adjuvant to Rituximab in Patients With Pemphigus: A Retrospective Cohort Study at a Tertiary Referral CenterActive, not recruitingNCT069492411 country
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)TerminatedNCT04598477Phase 321 countries
- Assessment of the 1-year Relapse Rate in Patients with Pemphigus Treated According to the Revised Pemphigus PNDSCompletedNCT069034941 country
- Comparing DCP and DAP for Pemphigus VulgarisCompletedNCT06846255Phase 41 country
- Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus VulgarisCompletedNCT066548171 country
- A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)CompletedNCT04598451Phase 321 countries
- Polyclonal Regulatory T Cells (PolyTregs) for PemphigusTerminatedNCT03239470Phase 11 country
- Dexamethasone Solution and Dexamethasone in Mucolox™CompletedNCT04540133Phase 21 country
- Identifying Factors Influencing In-Hospital Relapse in Pemphigus PatientsCompletedNCT061674081 country
- A Study of PRN1008 in Patients With PemphigusTerminatedNCT03762265Phase 319 countries
- Role of Tzanck Smear in Determining Pemphigus Vulgaris Disease ActivityStatus unknownNCT053381121 country
- A Study of PRN1008 in Adult Patients With Pemphigus VulgarisCompletedNCT02704429Phase 25 countries
- Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous PemphigoidStatus unknownNCT05594472Phase 31 country
- Validation of 5-Point Investigator Global Assessments for PemphigusStatus unknownNCT055347767 countries
- Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris PatientsStatus unknownNCT040962221 country
- A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)Status unknownNCT05303272Phase 41 country
- Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian PopulationStatus unknownNCT052849291 country
- Study of Efficacy and Safety of VAY736 in Patients With Pemphigus VulgarisTerminatedNCT01930175Phase 24 countries
- Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus VulgarisStatus unknownNCT04023149Phase 21 country
- Phenotypic and Functional Characterisation of Human B-cell Response in PemphigusStatus unknownNCT04117529Not applicable1 country
- A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With PemphigusCompletedNCT03334058Phase 25 countries
- A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)CompletedNCT02383589Phase 312 countries
- Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival BiopsyCompletedNCT04293718
- A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)TerminatedNCT03075904Phase 1/21 country